Role of platelet rich plasma in infertile females with thin endometrium

Not Applicable

Completed

Registration Number: CTRI/2022/05/042399

Lead Sponsor: not applicable

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Infertile female between 21-37 years with normal ovarian reserve (AMH:1.2-4 ng/ml;AFC:5-15) , patent both tubes and normal seminogram/ or mild male factor undergoing IUI for mild cervical factor and/ or unexplained infertility.

2. Persistent thin endometrial thickness <6 mm on >=1 cycle in previous cycle even after conventional treatment with estradiol valearate.

3. HB >11 gm% and platelets >1.5 lakhs

Exclusion Criteria

1.History of symptoms of platelet dysfunction such as easy bruisability, frequent nose-bleeds, heavy menstrual bleeding, bleeding gums or excessive bleeding during dental procedures.

2.Blood borne disease like Hepatitis B, Hepatitis C, Syphilis, HIV.

3.NSAIDs intake in 10 days before the procedure

4.Pt on anticoagulant therapy

5.Severe Male factor for infertility

6.Tubal factor for infertility

7.WHO class 1 and 3 ovulatory dysfunction

8.Mullerian abnormality

9.Ashermann Syndrome

10.Endometritis

11.Moderate /severe endometriosis

12.Active vaginal/cervix infection/pelvic inflammatory disease.

13.Any significant co-morbidity/ psychiatric disorder which compromise or interfere with consent giving/study participation/ follow up or interpretation of study.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1)Change in endometrium thickness. <br/ ><br>2)change in endometrium vascularity <br/ ><br>Timepoint: 1)baseline,36-40 hours <br/ ><br>2)baseline,36-40 hours

Secondary Outcome Measures

Name	Time	Method
1)positive pregnancy rate <br/ ><br>2)clinical pregnancy rate <br/ ><br>Timepoint: End point:The study will be stopped on achieving positive pregnancy or completion of three cycles of autologous PRP intrauterine instillation(whichever is earlier)